Setting & Participants
Outcomes & Measurements
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).Clin Trials. 2014; 11: 532-546
- A randomized trial of intensive versus standard blood-pressure control.N Engl J Med. 2015; 373: 2103-2116
- Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease: a secondary analysis of a randomized trial.Ann Intern Med. 2017; 167: 375-383
- Effects of intensive BP control in CKD.J Am Soc Nephrol. 2017; 28: 2721-2728
- Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate.Ann Intern Med. 2006; 145: 247-254
- KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.Kidney Int Suppl. 2013; 3: 1-150
- Renal Association clinical practice guidelines on acute kidney injury.Nephron Clin Pract. 2011; 118: c349-c390
- Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury.Kidney Int. 2009; 76: 422-427
- Candidate surrogate end points for ESRD after AKI.J Am Soc Nephrol. 2016; 27: 2851-2859
- Modeling Survival Data: Extending the Cox Model.Springer, New York, NY2000: 170-174
- Acute kidney injury, mortality, length of stay, and costs in hospitalized patients.J Am Soc Nephrol. 2005; 16: 3365-3370
- Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis.Am J Kidney Dis. 2009; 53: 961-973
- Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals.Clin J Am Soc Nephrol. 2014; 9: 12-20
- Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis.Kidney Int. 2012; 81: 442-448
- Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease.Kidney Int. 2009; 76: 893-899
- Risk factors for end-stage renal disease: 25-year follow-up.Arch Intern Med. 2009; 169: 342-350
- The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.N Engl J Med. 1994; 330: 877-884
- Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.JAMA. 2002; 288: 2421-2431
- Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.Lancet. 2016; 387: 435-443
- Blood pressure control in chronic kidney disease: is less really more?.J Am Soc Nephrol. 2010; 21: 1086-1092
- Long-term prognosis after acute kidney injury (AKI): what is the role of baseline kidney function and recovery? A systematic review.BMJ Open. 2015; 5: e006497
Complete author and article information (including a list of the members of the SPRINT Research Group) provided before references.
SPRINT Research Group: A list of the members of the SPRINT Research Group appears in the supplementary material accompanying Ambrosius et al
Authors’ Full Names and Academic Degrees: Michael V. Rocco, MD, MSCE, Kaycee M. Sink, MD, MAS, Laura C. Lovato, MS, Dawn F. Wolfgram, MD, Thomas B. Wiegmann, MD, Barry M. Wall, MD, Kausik Umanath, MD, MS, Frederic Rahbari-Oskoui, MD, MS, Anna C. Porter, MD, Roberto Pisoni, MD, Cora E. Lewis, MD, MSPH, Julia B. Lewis, MD, James P. Lash, MD, Lois A. Katz, MD, Amret T. Hawfield, MD, William E. Haley, MD, Barry I. Freedman, MD, Jamie P. Dwyer, MD, Paul E. Drawz, MD, MHS, MS, Mirela Dobre, MD, Alfred K. Cheung, MD, Ruth C. Campbell, MD, MSPH, Udayan Bhatt, MD, Srinivasan Beddhu, MD, Paul L. Kimmel, MD, David M. Reboussin, PhD, and Glenn M. Chertow, MD.
Authors’ Contributions: Research idea and study design: MVR, KMS, GMC, DMR; data acquisition: all authors except DMR and LCL, as these authors were involved with adjudication of AKI events: data analysis/interpretation: MVR, KMS, GMC, LCL; statistical analysis: LCL; supervision or mentorship: MVR, KMS, GMC. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.
Support: Supported by contracts ( HHSN268200900040C , HHSN268200900046C , HHSN268200900047C , HHSN268200900048C , and HHSN268200900049C ) and an interagency agreement (A-HL-13-002-001) from the NIH , including the NHLBI, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Institute of Neurological Disorders and Stroke. Several study sites were supported by Clinical and Translational Science Awards funded by the National Center for Advancing Translational Sciences of the NIH (Case Western Reserve University: UL1TR000439 ; Ohio State University: UL1RR025755 ; University of Pennsylvania: UL1RR024134 and UL1TR000003 ; Boston University: UL1RR025771 ; Stanford University: UL1TR000093 ; Tufts University: UL1RR025752 , UL1TR000073 , and UL1TR001064 ; University of Illinois: UL1TR000050 ; University of Pittsburgh: UL1TR000005 ; University of Texas Southwestern: 9U54TR000017-06 ; University of Utah: UL1TR000105-05 ; Vanderbilt University: UL1TR000445 ; George Washington University: UL1TR000075 ; University of California, Davis: UL1TR000002 ; University of Florida: UL1TR000064 ; University of Michigan: UL1TR000433 ; and Tulane University: P30GM103337 Centers of Biomedical Research Excellence Award National Institute of General Medical Sciences). The trial was also supported in part with respect to resources and the use of facilities by the Department of Veterans Affairs. Azilsartan and chlorthalidone (combined with azilsartan) were provided by Takeda Pharmaceuticals International Inc. The SPRINT Steering Committee was responsible for the design and conduct of the study, including the collection and management of the data. Scientists at the NIH as a group and the principal investigator of the Veterans Affairs clinical network had 1 vote on the Steering Committee of the trial. There were 7 voting members of the Steering Committee. The NIH, the US Department of Veterans Affairs, and the US government had no role in analysis and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Financial Disclosure: Dr Freedman reports research support from Novartis Pharmaceuticals and serving as a consultant for Ionis Pharmaceuticals. Dr Lewis reports serving as a consultant for Sanofi and Acaeogen. The other authors declare that they have no other relevant financial interests.